Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-04-05

AUTHORS

Masatsugu Hori, Ryozo Nagai, Tohru Izumi, Masunori Matsuzaki

ABSTRACT

Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF). However, few studies have compared its efficacy and safety with those of the widely used β-blocker carvedilol in Japanese patients with CHF. We designed a confirmatory trial of bisoprolol using carvedilol as a control drug; however, the trial was discontinued after an off-label use of bisoprolol was approved during the study. Bisoprolol and carvedilol were administered for 32 weeks in 31 and 28 patients, respectively. The mean maintenance doses of bisoprolol and carvedilol were 3.3 and 13.6 mg/day, respectively, and the mean durations of treatment were 188.2 and 172.9 days, respectively. Heart-rate changes were similar in both groups. The mean changes from baseline to Week 32 in left ventricular (LV) ejection fraction (EF) (bisoprolol vs carvedilol groups; 11.7 % ± 8.6 % vs 10.1 % ± 10.5 %), LV end-diastolic volume (−37.5 ± 48.7 vs −24.7 ± 29.4 ml), and LV end-systolic volume (−41.9 ± 43.0 vs −29.3 ± 25.9 ml) revealed a decrease in LV volume and an increase in LVEF in both groups. The cumulative event-free rate for a composite of cardiovascular death or admissions to hospital for worsening of CHF was 92.4 % and 94.7 % in the bisoprolol and carvedilol groups, respectively. Overall, 90.3 % and 85.7 % of patients were titrated up to the maintenance doses of bisoprolol and carvedilol, respectively. Bisoprolol, at half the dose used in other countries, is well tolerated and is as effective as carvedilol for treating Japanese patients with mild to moderate CHF. More... »

PAGES

238-247

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00380-013-0340-3

DOI

http://dx.doi.org/10.1007/s00380-013-0340-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008794029

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23559359


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bisoprolol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carbazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carvedilol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chronic Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Early Termination of Clinical Trials", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Admission", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Propanolamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stroke Volume", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ventricular Function, Left", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ventricular Remodeling", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, 537-8511, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416963.f", 
          "name": [
            "Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, 537-8511, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hori", 
        "givenName": "Masatsugu", 
        "id": "sg:person.01324324532.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324324532.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nagai", 
        "givenName": "Ryozo", 
        "id": "sg:person.0772176333.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772176333.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardio-Angiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Kanagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410786.c", 
          "name": [
            "Department of Cardio-Angiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Kanagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Izumi", 
        "givenName": "Tohru", 
        "id": "sg:person.0672551771.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672551771.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, 755-8505, Ube, Yamaguchi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268397.1", 
          "name": [
            "Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, 755-8505, Ube, Yamaguchi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsuzaki", 
        "givenName": "Masunori", 
        "id": "sg:person.01036165064.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036165064.24"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2013-04-05", 
    "datePublishedReg": "2013-04-05", 
    "description": "Bisoprolol fumarate (bisoprolol) is a \u03b2-blocker widely used to treat chronic heart failure (CHF). However, few studies have compared its efficacy and safety with those of the widely used \u03b2-blocker carvedilol in Japanese patients with CHF. We designed a confirmatory trial of bisoprolol using carvedilol as a control drug; however, the trial was discontinued after an off-label use of bisoprolol was approved during the study. Bisoprolol and carvedilol were administered for 32 weeks in 31 and 28 patients, respectively. The mean maintenance doses of bisoprolol and carvedilol were 3.3 and 13.6 mg/day, respectively, and the mean durations of treatment were 188.2 and 172.9 days, respectively. Heart-rate changes were similar in both groups. The mean changes from baseline to Week 32 in left ventricular (LV) ejection fraction (EF) (bisoprolol vs carvedilol groups; 11.7 % \u00b1 8.6 % vs 10.1 % \u00b1 10.5 %), LV end-diastolic volume (\u221237.5 \u00b1 48.7 vs \u221224.7 \u00b1 29.4 ml), and LV end-systolic volume (\u221241.9 \u00b1 43.0 vs \u221229.3 \u00b1 25.9 ml) revealed a decrease in LV volume and an increase in LVEF in both groups. The cumulative event-free rate for a composite of cardiovascular death or admissions to hospital for worsening of CHF was 92.4 % and 94.7 % in the bisoprolol and carvedilol groups, respectively. Overall, 90.3 % and 85.7 % of patients were titrated up to the maintenance doses of bisoprolol and carvedilol, respectively. Bisoprolol, at half the dose used in other countries, is well tolerated and is as effective as carvedilol for treating Japanese patients with mild to moderate CHF.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00380-013-0340-3", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1095887", 
        "issn": [
          "0910-8327", 
          "1615-2573"
        ], 
        "name": "Heart and Vessels", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "keywords": [
      "chronic heart failure", 
      "Japanese patients", 
      "maintenance doses", 
      "heart failure", 
      "ejection fraction", 
      "cumulative event-free rates", 
      "moderate chronic heart failure", 
      "left ventricular ejection fraction", 
      "LV end-systolic volume", 
      "LV end-diastolic volume", 
      "mean maintenance doses", 
      "event-free rate", 
      "\u03b2-blocker carvedilol", 
      "ventricular ejection fraction", 
      "end-diastolic volume", 
      "end-systolic volume", 
      "heart rate changes", 
      "carvedilol group", 
      "cardiovascular death", 
      "II study", 
      "label use", 
      "mean duration", 
      "week 32", 
      "mean change", 
      "\u03b2-blockers", 
      "LV volumes", 
      "patients", 
      "control drug", 
      "confirmatory trials", 
      "bisoprolol", 
      "carvedilol", 
      "doses", 
      "trials", 
      "efficacy", 
      "group", 
      "bisoprolol fumarate", 
      "days", 
      "safety", 
      "LVEF", 
      "failure", 
      "admission", 
      "fumarate", 
      "dose", 
      "administration", 
      "baseline", 
      "weeks", 
      "study", 
      "drugs", 
      "death", 
      "treatment", 
      "volume", 
      "duration", 
      "changes", 
      "decrease", 
      "rate", 
      "increase", 
      "use", 
      "fraction", 
      "countries", 
      "results", 
      "composites"
    ], 
    "name": "Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study", 
    "pagination": "238-247", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008794029"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00380-013-0340-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23559359"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00380-013-0340-3", 
      "https://app.dimensions.ai/details/publication/pub.1008794029"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_608.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00380-013-0340-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00380-013-0340-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00380-013-0340-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00380-013-0340-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00380-013-0340-3'


 

This table displays all metadata directly associated to this object as RDF triples.

256 TRIPLES      20 PREDICATES      112 URIs      104 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00380-013-0340-3 schema:about N33ac6310cf574755b02c88ebd4ee737e
2 N392c7e0ed04340b7a91ae7af7b69ba1d
3 N451c05d3c3f74f918da8231ec4ef5c36
4 N4ca02d26afad4e0cbcd119879a4d551d
5 N615d2454a4dc4d3984fb6c600d4f64ae
6 N682061f6140945c295b8ba3270a17e64
7 N75931a3f63754016aedc6849df2158d0
8 N75b9c0092f1042c8b69864f8fd6fdfdf
9 N7674963655b14b8683398bdd1a90a883
10 N7e54f05cddb540c9a8fb6a29c7712293
11 N858bf2ae8202454e9a012fba9fb461d2
12 Nbd8a84f88c0d4de29a32283dd7c132ea
13 Nd202d582611b4f37b759ccbf112e46fa
14 Ne2023dbef1624e2d9ff4061b88fa0e2f
15 Ne4584fde31b9479eb11104317d15e479
16 Ne50ca66324854e089be8d764266e5ad6
17 Ne55271516b5f4af28e693a7054fcee72
18 Ne647233d0c9544c5a897ae6f88b57bf7
19 Ne75b00b0f165413e87128796001c91e1
20 Ne7ae9657f1cb455d94ce9a124ac40cdf
21 Ned29fecabe60422c8206f4305e49e6e6
22 Nf08e54851b7b407b8c73aef389b553c8
23 Nf7b4d1e011d9438fb676d2774118bb7e
24 Nfa925e50cd424c8e9d1226011fe15e5a
25 Nfbc8a9496cf6475da82dfd382faab887
26 Nfc01ff5a9d094fa99085926102f6caba
27 anzsrc-for:11
28 anzsrc-for:1102
29 schema:author N807d7f1985cc453eb424587a7f586e24
30 schema:datePublished 2013-04-05
31 schema:datePublishedReg 2013-04-05
32 schema:description Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF). However, few studies have compared its efficacy and safety with those of the widely used β-blocker carvedilol in Japanese patients with CHF. We designed a confirmatory trial of bisoprolol using carvedilol as a control drug; however, the trial was discontinued after an off-label use of bisoprolol was approved during the study. Bisoprolol and carvedilol were administered for 32 weeks in 31 and 28 patients, respectively. The mean maintenance doses of bisoprolol and carvedilol were 3.3 and 13.6 mg/day, respectively, and the mean durations of treatment were 188.2 and 172.9 days, respectively. Heart-rate changes were similar in both groups. The mean changes from baseline to Week 32 in left ventricular (LV) ejection fraction (EF) (bisoprolol vs carvedilol groups; 11.7 % ± 8.6 % vs 10.1 % ± 10.5 %), LV end-diastolic volume (−37.5 ± 48.7 vs −24.7 ± 29.4 ml), and LV end-systolic volume (−41.9 ± 43.0 vs −29.3 ± 25.9 ml) revealed a decrease in LV volume and an increase in LVEF in both groups. The cumulative event-free rate for a composite of cardiovascular death or admissions to hospital for worsening of CHF was 92.4 % and 94.7 % in the bisoprolol and carvedilol groups, respectively. Overall, 90.3 % and 85.7 % of patients were titrated up to the maintenance doses of bisoprolol and carvedilol, respectively. Bisoprolol, at half the dose used in other countries, is well tolerated and is as effective as carvedilol for treating Japanese patients with mild to moderate CHF.
33 schema:genre article
34 schema:isAccessibleForFree false
35 schema:isPartOf N592f0cc74a6b4e26b1d89c63c0fb9aca
36 Nb516b8a80247460c9af8e8e56136b4ce
37 sg:journal.1095887
38 schema:keywords II study
39 Japanese patients
40 LV end-diastolic volume
41 LV end-systolic volume
42 LV volumes
43 LVEF
44 administration
45 admission
46 baseline
47 bisoprolol
48 bisoprolol fumarate
49 cardiovascular death
50 carvedilol
51 carvedilol group
52 changes
53 chronic heart failure
54 composites
55 confirmatory trials
56 control drug
57 countries
58 cumulative event-free rates
59 days
60 death
61 decrease
62 dose
63 doses
64 drugs
65 duration
66 efficacy
67 ejection fraction
68 end-diastolic volume
69 end-systolic volume
70 event-free rate
71 failure
72 fraction
73 fumarate
74 group
75 heart failure
76 heart rate changes
77 increase
78 label use
79 left ventricular ejection fraction
80 maintenance doses
81 mean change
82 mean duration
83 mean maintenance doses
84 moderate chronic heart failure
85 patients
86 rate
87 results
88 safety
89 study
90 treatment
91 trials
92 use
93 ventricular ejection fraction
94 volume
95 week 32
96 weeks
97 β-blocker carvedilol
98 β-blockers
99 schema:name Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study
100 schema:pagination 238-247
101 schema:productId N06b31fd13e4644a2b9ff2aa0ebc8545b
102 Nb6c81b8031b847efa34a3dd6e452651f
103 Nd667f8ab77b740b5999d89115723f5c2
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008794029
105 https://doi.org/10.1007/s00380-013-0340-3
106 schema:sdDatePublished 2022-11-24T20:58
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher N67a68592e2254c1da71540ac02457a85
109 schema:url https://doi.org/10.1007/s00380-013-0340-3
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N06b31fd13e4644a2b9ff2aa0ebc8545b schema:name dimensions_id
114 schema:value pub.1008794029
115 rdf:type schema:PropertyValue
116 N33ac6310cf574755b02c88ebd4ee737e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Time Factors
118 rdf:type schema:DefinedTerm
119 N34e4deed27c54ea59b149c16d37eabe0 rdf:first sg:person.0772176333.38
120 rdf:rest Na2b3daff18c040ef969813d89275dd55
121 N392c7e0ed04340b7a91ae7af7b69ba1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Carvedilol
123 rdf:type schema:DefinedTerm
124 N451c05d3c3f74f918da8231ec4ef5c36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Middle Aged
126 rdf:type schema:DefinedTerm
127 N4ca02d26afad4e0cbcd119879a4d551d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Patient Admission
129 rdf:type schema:DefinedTerm
130 N592f0cc74a6b4e26b1d89c63c0fb9aca schema:issueNumber 2
131 rdf:type schema:PublicationIssue
132 N5fe6de6454514efb9740e17ba8ae7c50 rdf:first sg:person.01036165064.24
133 rdf:rest rdf:nil
134 N615d2454a4dc4d3984fb6c600d4f64ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Ventricular Remodeling
136 rdf:type schema:DefinedTerm
137 N67a68592e2254c1da71540ac02457a85 schema:name Springer Nature - SN SciGraph project
138 rdf:type schema:Organization
139 N682061f6140945c295b8ba3270a17e64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Male
141 rdf:type schema:DefinedTerm
142 N75931a3f63754016aedc6849df2158d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Carbazoles
144 rdf:type schema:DefinedTerm
145 N75b9c0092f1042c8b69864f8fd6fdfdf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Stroke Volume
147 rdf:type schema:DefinedTerm
148 N7674963655b14b8683398bdd1a90a883 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Early Termination of Clinical Trials
150 rdf:type schema:DefinedTerm
151 N7e54f05cddb540c9a8fb6a29c7712293 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Disease-Free Survival
153 rdf:type schema:DefinedTerm
154 N807d7f1985cc453eb424587a7f586e24 rdf:first sg:person.01324324532.27
155 rdf:rest N34e4deed27c54ea59b149c16d37eabe0
156 N858bf2ae8202454e9a012fba9fb461d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Japan
158 rdf:type schema:DefinedTerm
159 Na2b3daff18c040ef969813d89275dd55 rdf:first sg:person.0672551771.07
160 rdf:rest N5fe6de6454514efb9740e17ba8ae7c50
161 Nb516b8a80247460c9af8e8e56136b4ce schema:volumeNumber 29
162 rdf:type schema:PublicationVolume
163 Nb6c81b8031b847efa34a3dd6e452651f schema:name doi
164 schema:value 10.1007/s00380-013-0340-3
165 rdf:type schema:PropertyValue
166 Nbd8a84f88c0d4de29a32283dd7c132ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Propanolamines
168 rdf:type schema:DefinedTerm
169 Nd202d582611b4f37b759ccbf112e46fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Ventricular Function, Left
171 rdf:type schema:DefinedTerm
172 Nd667f8ab77b740b5999d89115723f5c2 schema:name pubmed_id
173 schema:value 23559359
174 rdf:type schema:PropertyValue
175 Ne2023dbef1624e2d9ff4061b88fa0e2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Treatment Outcome
177 rdf:type schema:DefinedTerm
178 Ne4584fde31b9479eb11104317d15e479 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Bisoprolol
180 rdf:type schema:DefinedTerm
181 Ne50ca66324854e089be8d764266e5ad6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Prospective Studies
183 rdf:type schema:DefinedTerm
184 Ne55271516b5f4af28e693a7054fcee72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Humans
186 rdf:type schema:DefinedTerm
187 Ne647233d0c9544c5a897ae6f88b57bf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Drug Administration Schedule
189 rdf:type schema:DefinedTerm
190 Ne75b00b0f165413e87128796001c91e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Aged
192 rdf:type schema:DefinedTerm
193 Ne7ae9657f1cb455d94ce9a124ac40cdf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Double-Blind Method
195 rdf:type schema:DefinedTerm
196 Ned29fecabe60422c8206f4305e49e6e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Chronic Disease
198 rdf:type schema:DefinedTerm
199 Nf08e54851b7b407b8c73aef389b553c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Severity of Illness Index
201 rdf:type schema:DefinedTerm
202 Nf7b4d1e011d9438fb676d2774118bb7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Female
204 rdf:type schema:DefinedTerm
205 Nfa925e50cd424c8e9d1226011fe15e5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Heart Failure
207 rdf:type schema:DefinedTerm
208 Nfbc8a9496cf6475da82dfd382faab887 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Heart Rate
210 rdf:type schema:DefinedTerm
211 Nfc01ff5a9d094fa99085926102f6caba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Adrenergic beta-Antagonists
213 rdf:type schema:DefinedTerm
214 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
215 schema:name Medical and Health Sciences
216 rdf:type schema:DefinedTerm
217 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
218 schema:name Cardiorespiratory Medicine and Haematology
219 rdf:type schema:DefinedTerm
220 sg:journal.1095887 schema:issn 0910-8327
221 1615-2573
222 schema:name Heart and Vessels
223 schema:publisher Springer Nature
224 rdf:type schema:Periodical
225 sg:person.01036165064.24 schema:affiliation grid-institutes:grid.268397.1
226 schema:familyName Matsuzaki
227 schema:givenName Masunori
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036165064.24
229 rdf:type schema:Person
230 sg:person.01324324532.27 schema:affiliation grid-institutes:grid.416963.f
231 schema:familyName Hori
232 schema:givenName Masatsugu
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324324532.27
234 rdf:type schema:Person
235 sg:person.0672551771.07 schema:affiliation grid-institutes:grid.410786.c
236 schema:familyName Izumi
237 schema:givenName Tohru
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672551771.07
239 rdf:type schema:Person
240 sg:person.0772176333.38 schema:affiliation grid-institutes:grid.26999.3d
241 schema:familyName Nagai
242 schema:givenName Ryozo
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772176333.38
244 rdf:type schema:Person
245 grid-institutes:grid.268397.1 schema:alternateName Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, 755-8505, Ube, Yamaguchi, Japan
246 schema:name Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, 755-8505, Ube, Yamaguchi, Japan
247 rdf:type schema:Organization
248 grid-institutes:grid.26999.3d schema:alternateName Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
249 schema:name Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
250 rdf:type schema:Organization
251 grid-institutes:grid.410786.c schema:alternateName Department of Cardio-Angiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Kanagawa, Japan
252 schema:name Department of Cardio-Angiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, 252-0374, Sagamihara, Kanagawa, Japan
253 rdf:type schema:Organization
254 grid-institutes:grid.416963.f schema:alternateName Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, 537-8511, Osaka, Japan
255 schema:name Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, 537-8511, Osaka, Japan
256 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...